Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXM01 with Avelumab in Progressive Glioblastoma
NCT03750071Phase 2Unknown
- Sponsor
- Vaximm
- Start
- Nov 2018
- Primary completion
- Dec 2021
- Modality
- DNA Vaccines, Live Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vxm01 in glioblastoma (GBM), sponsored by Vaximm. Status: unknown.
02
Drugs
vxm01
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03750071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03750071.